At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 11 enrolled
Drug / intervention
AMG 994 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Multicenter, Open-label, Dose Exploration and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 994 Monotherapy and Combination of AMG 994 and AMG 404 in Subjects With Advanced Solid Tumors
In Brief
A Phase 1 clinical trial evaluating AMG 994 and AMG 404 for Advanced Solid Tumors. Completed, enrolled 11 participants across 17 sites in 10 countries.
Detailed Summary
The primary objective of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD)/maximum tolerated combination dose (MTCD) or recommended phase 2 dose (RP2D) of AMG 994 as monotherapy and AMG 994 in combination with AMG 404 in participants with advanced solid tumors.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumors
CountriesAustralia, Belgium, Canada, France, Germany, Japan, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartApr 2021
Primary CompletionJun 2023
TodayJul 2026
First PostedJan 27, 2021
Enrollment StartApr 29, 2021
Primary CompletionJun 5, 2023
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 5.4 years ago
Interventions
AMG 994drug
Administered as an intravenous (IV) infusion.
AMG 404drug
Administered as an intravenous (IV) infusion.